Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad(Centre Hospitalier de l’Université de Montréal), Noel W. Clarke(Salford Royal NHS Foundation Trust), Mototsugu Oya(Keio University), Neal D. Shore(Carolina Urologic Research Center), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), João Daniel Guedes(Hospital de Base), Cagatay Arslan(Izmir University), Niven Mehra(Radboud University Nijmegen), Francis Parnis(Centre for Cancer Biology), Emma Brown(University Hospital Southampton NHS Foundation Trust), Friederike Schlürmann(Centre Hospitalier de Cornouaille), Jae Young Joung(National Cancer Center), Mikio Sugimoto(Kagawa University Hospital), Oliver Sartor(Mayo Clinic in Arizona), Yuzhen Liu(AstraZeneca (United Kingdom)), Christian Poehlein(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Barker(AstraZeneca (United Kingdom)), Paula Michelle del Rosario(AstraZeneca (United Kingdom)), Andrew J. Armstrong(Duke University)
Cited by 283Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis